|
1
|
Henshaw RM (ed.): Sarcoma: A
Multidisciplinary Approach to Treatment. Springer, Cham, 2017.
|
|
2
|
Somaiah N and von Mehren M: New drugs and
combinations for the treatment of soft-tissue sarcoma: A review.
Cancer Manag Res. 4:397–411. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Uehara T, Fujiwara T, Takeda K, Kunisada
T, Ozaki T and Udono H: Immunotherapy for bone and soft tissue
sarcomas. Biomed Res Int. 2015(820813)2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Demicco EG, Maki RG, Lev DC and Lazar AJ:
New therapeutic targets in soft tissue sarcoma. Adv Anat Pathol.
19:170–180. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Amankwah EK, Conley AP and Reed DR:
Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol.
5:147–162. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Welter S, Grabellus F, Bauer S, Schuler M,
Eberhardt W, Tötsch M and Stamatis G: Growth patterns of lung
metastases from sarcoma: Prognostic and surgical implications from
histology. Interact Cardiovasc Thorac Surg. 15:612–617.
2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
ESMO/European Sarcoma Network Working
Group. Soft tissue and visceral sarcomas: Esmo clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
25(Suppl 3):iii102–iii112. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sharma P, Retz M, Siefker-Radtke A, Baron
A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, et
al: Nivolumab in metastatic urothelial carcinoma after platinum
therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial.
Lancet Oncol. 18:312–322. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Nielsen TO, Poulin NM and Ladanyi M:
Synovial sarcoma: Recent discoveries as a roadmap to new avenues
for therapy. Cancer Discov. 5:124–134. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Brunello A, Rizzato MD, Rastrelli M, Roma
A, Maruzzo M, Basso U, Fiduccia P, Buzzaccarini MS, Scarzello G,
Rossi CR and Zagonel V: Adjuvant chemotherapy for soft tissue
sarcomas: A 10-year mono-institutional experience. J Cancer Res
Clin Oncol. 142:679–685. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Guest JF, Panca M, Sladkevicius E, Gough N
and Linch M: Cost effectiveness of first-line treatment with
doxorubicin/ifosfamide compared to trabectedin monotherapy in the
management of advanced soft tissue sarcoma in Italy, Spain, and
Sweden. Sarcoma. 2013(725305)2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pervaiz N, Colterjohn N, Farrokhyar F,
Tozer R, Figueredo A and Ghert M: A systematic meta-analysis of
randomized controlled trials of adjuvant chemotherapy for localized
resectable soft-tissue sarcoma. Cancer. 113:573–581.
2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Casali PG: Adjuvant chemotherapy for soft
tissue sarcoma. Am Soc Clin Oncol Educ Book. e629–e633.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Pasquali S and Gronchi A: Neoadjuvant
chemotherapy in soft tissue sarcomas: Latest evidence and clinical
implications. Ther Adv Med Oncol. 9:415–429. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zagars GK, Ballo MT, Pisters PW, Pollock
RE, Patel SR, Benjamin RS and Evans HL: Prognostic factors for
patients with localized soft-tissue sarcoma treated with
conservation surgery and radiation therapy An analysis of 1225
patients. Cancer. 97:2530–2543. 2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Vlenterie M, Litière S, Rizzo E, Marréaud
S, Judson I, Gelderblom H, Le Cesne A, Wardelmann E, Messiou C,
Gronchi A and van der Graaf WT: Outcome of chemotherapy in advanced
synovial sarcoma patients: Review of 15 clinical trials from the
European organisation for research and treatment of cancer soft
tissue and bone sarcoma group; setting a new landmark for studies
in this entity. Eur J Cancer. 58:62–72. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Spurrell E, Fisher C, Thomas JM and Judson
IR: Prognostic factors in advanced synovial sarcoma: An analysis of
104 patients treated at the Royal Marsden Hospital. Ann Oncol.
16:437–444. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Salah S, Yaser S, Salem A, Al Mousa A, Abu
Sheikha A and Sultan I: Factors influencing survival in metastatic
synovial sarcoma: Importance of patterns of metastases and the
first-line chemotherapy regimen. Med Oncol. 30(639)2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Paoluzzi L, Cacavio A, Ghesani M,
Karambelkar A, Rapkiewicz A, Weber J and Rosen G: Response to
anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin
Sarcoma Res. 6(24)2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tawbi HAH, Burgess MA, Crowley J, Van Tine
BA, Hu J, Schuetze S, D'Angelo SP, Attia S, Priebat DA, Okuno SH,
et al: Safety and efficacy of PD-1 blockade using pembrolizumab in
patients with advanced soft tissue (STS) and bone sarcomas (BS):
Results of SARC028-A multicenter phase II study. J Clin Oncol.
34(11006)2016.
|
|
21
|
George S, Barysauskas CM, Solomon S,
Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Wagner AJ, Merriam
P, et al: Phase 2 study of nivolumab in metastatic leiomyosarcoma
of the uterus. J Clin Oncol. 34(11007)2016.
|
|
22
|
Bleloch JS, Ballim RD, Kimani S, Parkes J,
Panieri E, Willmer T and Prince S: Managing sarcoma: Where have we
come from and where are we going? Ther Adv Med Oncol. 9:637–659.
2017.PubMed/NCBI View Article : Google Scholar
|
